Eric J. Feldman, M.D.

Medical Oncology
Eric Feldman

Dr. Eric Feldman is a graduate of Tulane University and New York Medical College and did his clinical training in Medicine and Heme/Onc at the Westchester County Medical Center. He also did some specialized clinical training at the Fred Hutchinson Cancer Center. From 1986 to 1991, he was on the faculty at New York Medical College, where he directed the leukemia programs. He then spent two years in the Hematology Department at MD Anderson in Houston. Dr. Feldman joined the Division of Hematology and Medical Oncology at Weill-Cornell in 1999 to become Director of the Leukemia Program. He has been Professor of Medicine at Weill Cornell Medical College and Attending Physician at the New York-Presbyterian Hospital since 2003.

Dr. Feldman has established a national and international reputation as an expert in leukemia clinical research and patient care. He is also experienced in the care of patients undergoing autologous and allogeneic stem cell transplantation and serves as an attending physician on that service. In 2007, Dr. Feldman was appointed Director of Hematological Malignancies at Weill Cornell. In this capacity, he oversees the Leukemia Program, the Lymphoma/Myeloma Program and the Bone Marrow Transplant Program.

Dr. Feldman's research efforts have been focused on defining the role of new chemotherapeutic and biotherapeutic agents in the treatment of leukemia and on understanding the biology of leukemic cells as it relates to response to chemotherapy. He has also focused on the use of gene therapy strategies in leukemia. He has had a productive academic career, publishing widely in the area of the biology and/or treatment of leukemia, with more than 112 peer reviewed manuscripts in prestigious journals.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


Published Articles


1.    Feldman EJ, Ahmed T, Friedland ML: Biologic tumor markers, J.Clin Ther 16:95-111, 1986.


2.    Arlin Z, Ahmed T, Mittelman A, Feldman EJ, Mehta R, Weinstein P, Rieber E, Sullivan P, Baskind P: A new regimen of amsacrine with high dose cytarabine is safe and effective therapy for acute leukemia. J Clin Onc 5:371-375,1987.


3.    Arlin ZA, Mehta RK, Feldman EJ, Sullivan P, Pucillo A: Amsacrine treatment of patients with supraventricular arrythmias and acute leukemia. Cancer Chemotherapy Pharmacol 99:163-164, 1987.


4.    Feldman EJ, Arlin ZA, Sullivan P, Engleking C. Preventing amsacrine-induced cardiac arrythmias. J clin Oncol, 1987, Dec; 5 (12): 2041


5.    Arlin ZA, Feldman EJ, Kempin S, Ahmed T, Mittelman A, Savona S, Baskind P, Sullivan P, Fuhr HG, Mertelsmann R: Amsacrine with high dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adults. Blood 72(2):433-435,1988.


6.    Puccio CA, Feldman EJ, Arlin ZA: Amsacrine is safe in patients with ventricular ectopy. Amer J Hematol 28:197-198, 1988.


7.    Feldman EJ, Arlin ZA: Modern management of chronic myelogenous leukemia (CML). Cancer Investigation 6:737-742,1988


8.    Arlin ZA, Feldman EJ. Treatment of acute promyelocytic leukemia. Blood 1989 Oct; 74 (5): 1858


9.    Ahmed T, Ciavarell D, Feldman EJ, Ascensao J, Hussain F, Engelking C, Gingrich S, Mittelman A, Coleman M, Arlin ZA: High dose, potentially myeloablative chemotherapy for patients with advanced Hodgkin’s disease. Leukemia 3:19-22, 1989.




10.    Arlin ZA, Feldman EJ: Ahmed T, Liebowitz D, Shapiro LR, Wilmot PL: Philadelphia chromosome (Ph1)-Positive acute lympho-blastic leukemia

(ALL) is resistant to effective therapy for Ph1-negative ALL. Acta Haemat

81:217-218, 1989.


11.    Arlin Z, Feldman EJ: Can we increase the cure rate of adults with acute lymphoblastic leukemia? Leukemia 3:318-320,1989


12. Feldman EJ, Arlin ZA, Ahmed T, Mittelman A, Ascensao JL, Puccio CA, Coombe N, Baskind P. Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage. Acta Haematol. 1989;82(3):117-21.


13.    Arlin ZA, Hagenbeek A, Feldman EJ, Andreef M: Implications of leukemia “Cell Kill” for the treatment of acute myelogenous leukemia (AML); Can the cure rate be increased? Acta Haematol 82:175-178, 1989.


14.    Arlin ZA, Case DC, Wiernik P, Moore J, Feldman EJ, Saletan S, Desi P, Sia L, Cartwright K, the Lederle Cooperative Group: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adults with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183, 1989.


15.    Mittelman A, Savona S, Puccio C, Chun H, Ahmed T, Feldman EJ, Sullivan P, Arnold P,Arlin Z: Phase II trial of fludarabine phosphate( F-Ara-AMP) in patients with advanced head and neck cancer. Invest New Drugs 8: 565-567, 1990.


16.    Abolhassani M, Riley WM, Feldman E, Arlin Z, Chiao JW. Two separate

   inducing proteins for human myeloid leukemia cells and their isolation from normal lymphocytes. Proc Soc Exp Biol Med 1990 Nov;195(2):288-91


17.   Feldman EJ, Biguzzi S, Ahmed, T., Mittelman A, Puccio C, Baskind P, Arlin ZA: Preliminary experience with short course high-dose mitoxantrone in combination with high-dose cytarabine in patients with acute leukemia and blastic phase of chronic myelogenous leukemia. Leukemia and Lymphoma. 3:209-211, 1990.


18.   Arlin Z, Feldman E, Ahmed T, Mittelman A, Puccio C, Biguzzi S: Intensive Chemotherapy with Interferon for induction of True Remission in Chronic Phase of Chronic Myelogenous Leukemia. Cancer Investigation, 8(2)303, 1


19.   Arlin ZA, Feldman EJ. Treatment of DIC associated with APL. Blood, 1990 Dec 1; 76(11): 2418


20.   Arlin ZA, Feldman EJ, Mittelman Ahmed T, Puccio C, Chun HG, Cook P, Baskind P, Marboe C, Mehta RK: Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 68:1198-2000, 1991.


21.   Grant S, Arlin ZA, Gewitz D, Feldman E: Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 5:336-339, 1991.


22.   Arlin ZA, Hiddeman W, Feldman EJ, Mittelman A, Ahmed T: Further thoughts on “Cell Kill” in acute leukemia. Acta Haematol 85:1-5, 1991


23.   Ahmed T, Wuest D, Ciavarella D, Ayello J, Feldman EJ, Biguzzi S, Gulati S, Hussain F, Mittelman A, Ascensao JL: Marrow storage techniques: A clinical comparison of refrigeration versus cryopreservation. Acta haematol 85: 173-178, 1991.


24.   Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman RD, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA: Loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9:1562-1569, 1991.


25.   Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Puccio C, Cook P, Chun HG: “Quality” Remissions: A new target of induction therapy in acute leukemia and the next step in developing curative treatment. Semin in hemat 28:44-47, 1991.


26.    Abraham NG, Feldman E, Falck JR, Lutton JD, Schwartzman ML: Modification of erythropoiesis by novel human bone marrow cytochrome P450-dependent metabolites of archidonic acid. Blood 78:1461-1466, 1991.


27.   Arlin Z, Feldman E, Finger LR, Ahmed T: Age, Phenotype, and curability in acute myelogenous leukemia. Cancer Invest 9:655-667, 1991.


28.   Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, cook P, Puccio C, Baskind P, Arnold P, Razis ED, Et al: Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5:712-714, 1991.


29.   Kantarjian HM, Keating MJ, Estey EH, O’Brien S, Pierce S, Beran M, Koller C, Feldman EJ, Talpaz M: Treatment of advanced stages of philadelphia chromosome-positive chronic myelogenous leukemia with interferon- and low dose cytarabine. Leukemia 5:712-714, 1991.


30.   Kantarjian HM, Smith T, Estey E, Polyzos A, O’Brien S, Pierce S, Beran M, Feldman EJ, MJ. Prognostic significant of elelvated serum beta-2 microglobulin levels in adult acute lymphocytic leukemia. Am J Med 1992 Dec; 93; (6):599-604.


31.   Feldman EJ, Arlin Z, Ahmed T, Mittelman A, Puccio, Chun H, Cook P, Baskind P: Homoharringtonine is safe and effective for patients with acute myelogenous leukemia (I). Leukemia 6(11):1189-91, 1992.


32.   Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P: Homoharringtonine in combination with cytarabine for patients with acute myelogenous luekemia (II). Leukemia 6(11);1189-91, 1992.


33. Arlin ZA, Feldman EJ, Finger L. Decter J, cook P. Ahmed T, Puccio C, Chun H, A: Improving the “Quality of remission induction” therapy: A necessary step for increasing the cure rate in acute myelogenous leukemia. Cancer Investigation 10:183-184, 1992.


34.   Arlin ZA, Feldman EJ, Cook P, Mittelman A, Chun HG, Puccio C, Helson L. Amsacrine retains a special role supporting Food and Drug Administration approval. J Clin Oncol, 1992 Jan; 10(1) 169


35. Kreis W, Lesser M, Budman DR, Arlin Z, DeAngelis L, Basking P, Feldman EJ, Akerman S: Phenotypic Analysis of 1-B-D-arabinofuranosylcytosine deamination in patients with Response. Cancer Chemotherapy Pharmacology:30(2):126-130, 1992.


36.   Feldman EJ, Keating M: Fludarabine in the treatment of lymphoproliferative malignancies. Cancer Investigation, 11:(3)314-318, 1993.


37.   Feldman EJ, Alberts DS, Arlin ZA, Ahmed T, Mittelman A, Baskind P, Peng Y-M, Baier , Plezia P: Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol Vol. 11 No. 10, 2002-2009, 1993.


38.   Razis E, Arlin ZA, Ahmed T, Feldman EJ, Puccio C, Cook P, Chun HG, Helson L, Mittelman A: The incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta haematologics 91:171-174, 1994.


39.   Ahmed T, Cook P, Feldman E, Coombe N, Puccio, Mittelman A, Chun H, Coleman M, Helson L: Phase I-II trial of high dose ara-c, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas. Leukemia Vol 8 No 4 (April) pp. 531-534, 1994.


40.   Razis ED, Samonis G, Cook P, Beer M, Mittelman A, Lake DE, Feldman EJ, Puccio C, Ahmed T: TMJ: A well-tolerated high dose regimen for the adjuvant chemotherapy of high risk breast cancer. Journal of Medicine Vol 25, No 3 &4, pp 241-250, 1994.


41.   Xun Li, Jianping Gong, Feldman EJ, Seiter K, Traganos F, Darzynkiewicz: apoptotic cell death during treatment of leukemias. Leukemia and Lymphomas Vol. 13, Suppl. 1 pp 65-70, 1994.


42.   Seiter K, Miller Jr, WH, Feldman EJ, Ahmed T, Arlin Z: Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia. Leukemia Vol 9, No. 1. (January)pp. 15-18 1995.


43.   Lederman C, Weisberger J, Seiter K, Feldman EJ: Differentiation of extramedullary acute promyelocytic leukemia by all-trans-retinoic acid. Leukemia and Lymphoma, Vol . 18, pp 189-193, 1995.


44.   Feldman EJ: Acute myelogenous leukemia in the older patient. Seminars in Oncology vol 22, No. 1 Suppl A (February), 1995 pp 21-24.


45.   Ahmed T, Lake D, Feldman EJ, Seiter K, Ali M, Beer M: Marrow transplantation for Hodgkin’s disease: points to ponder. Leukemia and Lymphoma vol 15, Suppl 1, pp25-26, 1995.


46.   Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J, Rios MB, Smith TL, Calvert L, Deisseroth AB: Collection of peripheral-blood diploid cells with Chronic Myelogenous Leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol Vol 13, No3 (march) pp. 553-559, 1995.


47.   Seiter K, Feldman EJ, Traganos F, Li X, Halicka HD, Darzynkiewicz Z, Lederman CA, Romero MB, Ahmed T: Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Leukemia, Vol 9, No. 11, pp1961-1966.


48.   Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA: Homoharringtonine in Patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia, Vol 10, No. 1, pp 40-43, 1996.


49.   Ahmed T, Lake D, Feldman EJ, Seiter K, Helson L, Mittelman A, Puccio C, Chun Hoo, Grima K, Akhtar T, Perchick J, Niazi Z, Preti R. Papish S, Waintraub S, Katz , Berk G, Coleman M, Beer M: Factors influencing prognosis after dose-intensive therapy for current or refractory Hodgkin’s disease. Results of sequential trials: A case for treating patients with resistant disease in: R. Sackstein, W.E. Janssen, GJ Elfenbein (eds). Bone Marrow Transplantation: Foundation for the 21st Century. Annals of the New York Academy of Sciences, Vol 770, New York, 1996.


50.   Easaw SJ, Lake DE, Beer M, Seiter K, Feldman EJ, Ahmed T: Graft-versus-Host disease: possible higher risk for African-American patients. Cancer 78:1492-1497, 1996.


51.   Xu W, Seiter K, Feldman E, Ahmed T, Chiao JW: The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood. 1996 Jun 1;87(11):4502-6.


52.   Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee t, Megherian L, Seiter K, Scheinberg D, Gold D. Cytarabine with high dose mitoxantrone induces rapid complete remissions in adult acute leukemia patients without the use of vincristine or prednisone. Journal of Clinical Oncology, 14:2480, 1996.


53.   Traganos F, Seiter K, Feldman E, Halicka D, Traganos, F, Darzynkiewicz Z: Induction of apoptosis by camptothecin and topotecan. Annals of the New York Academy of Sciences Vol 803, pp1-10 Dec 13, 1996.


54.   Halicka HD, Seiter K, Feldman EJ, Traganos F, Mittelman A, Ahmed T, Darzynkiewicz Z. Cell cycle specificity of apoptosis during treatment of leukemias. Apoptosis 2:25-39, 1997.


55.   Seiter K, Feldman EJ, Halicka D, Traganos, F, Darzynkiewicz, A, Lake D, Ahmed T: Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of Clin Oncol, Vol 15, No. 1, pp 44-51, 1997.


56.   Ahmed T, Lake DE, Beer M, Feldman EJ, Preti RA, Seiter K, Helson L, Mittelman A, Kancherla R, Ascensao J, Akhtar T, Cook P, Goldberg R, Coleman M: Single and double auto-transplant for relapsing/refractory Hodgkin’s disease: results of two consecutive trials. Bone Marrow Transplantation, Vol 19, pp449-454, 1997.


57. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC, Beer M, Ahmed T: A randomized trial of high versus standard dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia Vol 11: 485-489, 1997.


58. Feldman EJ, Ahmed T, Lutton JD, Farley T, Tani K, Asano, Freund M, Abraham NG: Adenovirus mediated alpha interferon (IFN-) Gene Transfer in CD34 cells and CML mononuclear cells. Stem Cells, 15:386-395, 1997.


59. Feldman EJ: High-dose mitoxantrone in acute leukemia: New York Medical College experience, European Journal of Cancer Care: 6:Suppl 1, pp27-32.


60. Chiao JW, Turo K, Yang YM, Feldman EJ, Traganos F, Halicka D, Kancherla R, Fatora SR, Ahmed T, McMichael J. Modulating activity of human chorionic gonadotropin on growth and tumorigenesis of prostate cancer cells. Molecular Urology, Vol 2, No. 2, 57-63.


61. Wagener F, Feldman EJ, DeWitte T, Abraham NG: Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selection in vascular endothelial cells (44197). Heme and Adhesion Molecule Expression. P. 456-463, 1998.


62. Ahmed T, Lutton JD, Feldman EJ, Tani K, Asano S, Abraham N: Gene Transfer of Alpha Interferon into hematopoietic stem cells. Leukemia Research 22(2), 119-124, 1998.


63. Chiao JW, Wei Xu, Seiter K, Feldman EJ, Ahmed T: Neuro-leukin medication differentiation induction of myelogenous leukemia cells. Leukemia Research Jan; 23(1)18, 1999.


64.   O’Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreef M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M: Sequential Homoharringtonine and Interferon Alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999, June 15; (93)4149-53.


65.   Feldman EJ, Seiter K, Chiao JW, Halicka HD, Traganos F, Fatora SR, McMichael J,Baskind P, Goff H, Beer M, Ahmed T, Darzynkiewicz: In Vitro effects and clinical evaluation of a human chorionic gonadotrophin preparation in acute leukemia. Leukemia1998, Nov 12(11) 1749-55.


66.   Feldman EJ, Seiter K, Halicka HD, Traganos F, Daryznkiewicz Z, Goff H, Beer M, Santos S, Ahmed T: Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia. Leukemia/Lymphoma. Leuk Lymphoma July;38(3-4) 309-315 2000.


67.   Papageorgio C, Seiter K, Feldman EJ: Therapy-Related myelodysplastic syndrome in adults with neurofibromatosis, Leukemia Lymphoma, Feb; 32(5-6) 605-608, 1999.


68.   Quan S, Seiter K, Feldman E, Yang L, Argani I, Farley TJ, Abraham NG, Ahmed T.

Human CD34 hematopoietic cells transduced by retrovirus-mediated interferon alpha gene maintains regeneration capacity and engraftment in NOD/SCID mice. Exp Hematol 1999 Oct;27(10):1511-8.


69.   Stein M, Feldman E, Seiter K, Chaio JW, Goff H, Beer M, Ahmed T: Cyclosporine-induced-autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion. Bone Marrow Transplant 1999. Nov; 24(10):1075-7.


70.    Koller CA, Kantarjian HM, Feldman EJ, O’Brien S, Rios MB, Estey E, Keating M A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.

Cancer. 1999 Dec 1;86(11):2246-51.


71. Sabaawy HM, Ikehara S, Adachi Y, Quan S, Feldman E, Kancherla R, Abraham NG, Ahmed T. Enhancement of 5-fluorouracil cytotoxicity on human colon cancer celss by Int J Oncol. 1999 Jun;14(6):1143-51.


72. Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol. 1999;101(2):82-8


73.    Quan S, Feldman E, Yang L, Wagener FA, Farley TJ, Abraham NG,

Ahmed T. Distinct effect of retroviral-mediated IFN-alpha gene transfer on human erythroleukemic and CD34 cell growth and differentiation. J Hematother Stem Cell Res 1999 Oct;8(5):491-502


74. Deptala A, Halicka HD, Salomon T, Gorczyca W, Seiter K, FeldmanEJ,Traganos F, Darzynkiewicz Z. Malignancy: A New Approach to the Analysis of Apoptosis in the

Leukemic Subpopulation by Flow Cytometry Using a CD45 Gating Strategy. Hematol 1999;4(2):113-121


75. Seiter K, Feldman EJ, Dorota Halicka H, Deptala A, Traganos F, Burke HB, Hoang A, Goff H, Pozzuoli M, Kancherla R, Darzynkiewicz Z, Ahmed T. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia. Br J Haematol 2000 Jan;108(1):40-7


76. Feldman EJ: High dose cytarabine-based therapy in adults with acute lymphoblastic

leukemia. Leuk Res. 2000 Mar;24(3):189-91,


77. Seiter K, Feldman EJ, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, Papageorgio C, Weiss M, Kancherla R, Ahmed T Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 2001 Jun;15(6):963-70


78.    Feldman EJ. Commentary: dose intensive chemotherapy in acute myeloid leukemia.

Leuk Res 2001 Mar;25(3):217-9


79. Seiter K, Liu D, Feldman EJ, Siddiqui AD, Hoang A, Baskind P, Kancherla R, T.Intravenous bolus topotecan in patients with myelodysplastic syndrome.Leukemia Lymphoma. 2001 Sep-Oct;42(5):963-8.


80.    Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15;99(10):3530-9.


81. Cragg L, Andreef M, Feldman E, Murgo A, Winning M, Roberts J, Tombes MB, Roboz G, Grant S. Phase I trial and correlative studies of bryostatin 1 ( NSC 399555 ) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clinical Cancer Res. 2002 July 8(7),2123-2133


82.    Roboz G, Knovich M, Bayer R, Schuster M, Seiter K, Powell B, Woodruff R, Silver R, Frankel A, Feldman E. Efficacy and safety of Gemtuzumab Ozogamicin in patients with poor prognosis Acute myeloid leukemia. Leuk Lymphoma 2002 October 43(5) 1951-1956


83.    Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N. Treatment of Relapsed or Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody HuM195. Leukemia 2003 17 314-318


84.    Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma. Clin Lymphoma. 2002 Dec;3(3):184-188



85.    Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver R. The Emergence of Philadelphia negative, trisomy 8 positive cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hem 2003 31 702-707



86.   Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in

adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13):4325-36. Epub 2002 Aug 01


87.   Giles FJ, Feldman EJ, Roboz GJ, Larson RA, Mamus SW, Cortes JE, Verstovsek S, Faderl S, Talpaz M, Beran M, Albitar M, O'Brien SM, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

Leuk Res. 2003 Dec;27(12):1091-6.


88. Feldman EJ. Monoclonal antibody therapy in acute myeloid leukemia. Curr Hematol Rep. 2003 Jan; 2(1): 73-7.


89.    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, FeldmanEJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM. Epratuzumab, a humanized anti

CD22 antibody in aggressive non-Hodgkins lymphoma: Phase I/II clinical trial results. Clin Cancer Res 2004 Aug 15; 10(16): 5327-34.


90.   Silver RT, Bennett JM, Deininger M, Feldman E, Rafii S, Silverstein RL, Solberg LA,

Spivak JL. The second international congress on myeloproliferative and myelodysplastic syndromes. Leuk Res. 2004 Sep;28(9):979-85.



91.    Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, FeldmanE,Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood. 2005 Jan 1;105(1):335-40.


92.    Feldman EJ . Farnesyltransferase inhibitors in myelodysplastic syndrome Curr Hematol Rep. 2005 May;4(3):186-90.



93.   Feldman EJ, Brandwein J, Stone, R, Kalaycio M, Moore. J. O’Connor J,Wedel N, Roboz GJ, Miller C, Chopra, R, Jurcic JC, Brown R, Ehmann WC, Schulmann P, Frankel SR, De Angelo D, Scheinberg D. Phase III randomized multicenter study of lintuzumab in combination with chemotherapy versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin Oncol. 2005 Jun 20;23(18):4110-6.

. .

94. Seiter K, Liu D, Feldman E, Shi Q, Qureshi A, Arshad M, Walia T, Naseer N, Baskind P, Ahmed T. Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma. 2006 Mar;47(3):425-32.


95. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006 Jan 1;107(1):293-300. Epub 2005 Sep 8.


96.   Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD,

Cooper M, Bilgrami SF, Ferrant A, Daenaen S, Karsted V, Cahill A, Albitar M, Kantarjian H, O’Brien S, Feldman E. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 2006, Mar 27 (epub ahead of print)


97. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilla M, Schuster MW, Laurent D, Feldman EJ. Phase I study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 2006 Jun;20 (6):952-7


98.    Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, Feldman EJ, Bohlen P, Zhu Z, Sun H, Kussie P, Rafii S. Activation of FGFR1beta signaling pathway promote4s survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia, 2006 Jun; 20(6):979-86


99. Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT. A study of reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using campath-1H as part of a graft-versus-host disease strategy. Biol Blood Marrow Transplant, 2006 Aug;12 (8): 868-75


100. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garret-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2006, Nov 2


101. List A, Dewald G, Bennett, J, Giagoundis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 Oct 5;355(14): 1456-65


102. Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curciso TJ, Wilkes M, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol, 2006 Dec 4;


103. Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin’s) lymphoma. Clin Cancer Res 2006 Oct 1;12 (19): 5809-16


104. Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Furman RR, Rossi A, Jhaveri K, Feldman EJ, Leonard JP. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy for indolent non-Hodgkin lymphoma. Leuk Res. 2007 Aug:31 (8): 1141-4. Epub 2007 May 1.


105. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitaar M, Feldman EJ, Roboz GJ. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007 Jul; 31(7):891-7


106. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion –dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 1; 111(1):86-93. Epub 2007 Sept 24.


107. Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman EJ, Rafii S. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood. 2008 Feb 15;111(4): 1951-61. Epub 2007 Nov 16.


108. Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Lowenberg B, Stone RM, DePorre P, Wang Y, Karp JE. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008 Mar 1;111(5):2589-96. Epub 2007 Dec 26.


109. Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008 Mar 17. [Epub ahead of print崀㰀戀爀⼀㸀㰀戀爀⼀㸀     ㄀㄀ ⸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀刀椀稀稀椀攀爀椀 䐀䄀Ⰰ 䘀攀氀搀洀愀渀 䔀䨀Ⰰ 䐀椀瀀攀爀猀椀漀 䨀䘀Ⰰ 䜀愀戀爀愀椀氀 一Ⰰ 匀琀漀挀欀 圀Ⰰ 匀琀爀愀椀爀 刀Ⰰ 刀椀瘀攀爀愀 嘀䴀Ⰰ 䄀氀戀椀琀愀爀 䴀Ⰰ 䈀攀搀爀漀猀椀愀渀 䌀䰀Ⰰ 䜀椀氀攀猀 䘀䨀⸀ 䄀 瀀栀愀猀攀 ㈀ 䌀氀椀渀椀挀愀氀 吀爀椀愀氀 漀昀 䐀攀昀漀爀漀氀椀洀甀猀 ⠀䄀倀㈀㌀㔀㜀㌀Ⰰ 䴀䬀ⴀ㠀㘀㘀㤀⤀Ⰰ 愀 一漀瘀攀氀 䴀愀洀洀愀氀椀愀渀 吀愀爀最攀琀 漀昀 刀愀瀀愀洀礀挀椀渀 䤀渀栀椀戀椀琀漀爀Ⰰ 椀渀 瀀愀琀椀攀渀琀猀 眀椀琀栀 刀攀氀愀瀀猀攀搀 漀爀 刀攀昀爀愀挀琀漀爀礀 栀攀洀愀琀漀氀漀最椀挀 䴀愀氀椀最渀愀渀挀椀攀猀⸀ 䌀氀椀渀 䌀愀渀挀攀爀 刀攀猀⸀ ㈀  㠀 䴀愀礀 ㄀㬀㄀㐀⠀㤀⤀㨀㈀㜀㔀㘀ⴀ㘀㈀⸀ 㰀戀爀⼀㸀 㰀戀爀⼀㸀㰀戀爀⼀㸀      ㄀㄀㄀⸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀圀攀琀稀氀攀爀 䴀Ⰰ 䐀漀渀漀栀甀攀 䬀䄀Ⰰ 伀搀攀渀椀欀攀 伀䴀Ⰰ 䘀攀氀搀洀愀渀 䔀䨀Ⰰ 䠀甀爀搀 䐀䐀Ⰰ 匀琀漀渀攀 刀䴀Ⰰ 圀攀猀琀攀爀昀攀氀琀 倀Ⰰ 䈀氀漀漀洀昀椀攀氀搀 䌀䐀Ⰰ 䰀愀爀猀漀渀 刀䄀⸀ 䘀攀愀猀椀戀椀氀椀琀礀 漀昀 愀搀洀椀渀椀猀琀攀爀椀渀最 伀戀氀椀洀攀爀猀攀渀 ⠀䜀㌀㄀㄀㌀㤀㬀䜀攀渀愀猀攀渀猀攀⤀ 眀椀琀栀 椀洀愀琀椀渀椀戀 洀攀猀礀氀愀琀攀 椀渀 瀀愀琀椀攀渀琀猀 眀椀琀栀 椀洀愀琀椀渀椀戀 爀攀猀椀猀琀愀渀琀 挀栀爀漀渀椀挀 洀礀攀氀漀椀搀 氀攀甀欀攀洀椀愀ⴀ䌀愀渀挀攀爀 愀渀搀 氀攀甀欀攀洀椀愀 最爀漀甀瀀 䈀 猀琀甀搀礀 ㄀ ㄀ 㜀⸀ 䰀攀甀欀 䰀礀洀瀀栀漀洀愀⸀ ㈀  㠀 䄀瀀爀 㐀㨀㄀ⴀ㔀⸀ 嬀䔀瀀甀戀 愀栀攀愀搀 漀昀 瀀爀椀渀琀崀㰀戀爀⼀㸀㰀戀爀⼀㸀     ㄀㄀㈀⸀☀渀戀猀瀀㬀☀渀戀猀瀀㬀☀渀戀猀瀀㬀䘀攀氀搀洀愀渀 䔀䨀Ⰰ 䌀漀爀琀攀猀 䨀Ⰰ 䐀攀䄀渀最攀氀漀 䐀䨀Ⰰ 䠀漀氀礀漀愀欀攀 吀Ⰰ 匀椀洀漀渀猀猀漀渀 䈀Ⰰ 伀鈀䈀爀椀攀渀 匀䜀Ⰰ 刀攀椀昀昀攀爀猀 䨀Ⰰ 吀甀爀渀攀爀 䄀刀Ⰰ 刀漀戀漀稀 䜀䨀Ⰰ 䰀椀瀀琀漀渀 䨀䠀Ⰰ 䴀愀氀漀椀猀攀氀 䘀Ⰰ 䌀漀氀漀洀愀琀 倀Ⰰ 䴀愀爀琀椀渀攀氀氀椀 䜀Ⰰ 一elsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A. The use of Lonafarnib in Myelodysplastic Syndrome and Chronic Myelomonocytic. Leukemia, In Press.

Honors and Awards

AOA Alumni Award - New York Medical College, 2007